At LINC 2017 (24–27 January, Leipzig, Germany), Sean Lyden (Cleveland Clinic, Cleveland, USA) presented an update on the 12-month results of the European and US cohorts of the ILLUMENATE randomised controlled trials, which are investigating the use of the Stellarex (Spectranetics) drug-coated balloon to treat peripheral arterial disease. Vascular News caught up with Lyden after his presentation, to hear the highlight results and their significance.
